Free Trial
NASDAQ:IBRX

ImmunityBio Q2 2025 Earnings Report

ImmunityBio logo
$2.40 +0.02 (+0.84%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.41 +0.01 (+0.42%)
As of 08/7/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.10
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$26.43 million
Expected Revenue
$21.95 million
Beat/Miss
Beat by +$4.48 million
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ImmunityBio's Q3 2025 earnings is scheduled for Monday, August 11, 2025

ImmunityBio Earnings Headlines

IBRX Sales Soar 2,540%
Critical AI announcement set to ignite AI 2.0
Markets are jittery. Rallies fade. Sectors rotate overnight. And the true impact of new tariffs and policy shifts hasn’t even hit the data yet. That’s why smart traders are turning to a strategy built for exactly this kind of market—fast, simple, and designed to react to real price action, not predictions.
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX), a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

View ImmunityBio Profile

More Earnings Resources from MarketBeat